{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=42",
    "query": {
      "intervention": "Control II",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 2668,
    "total_pages": 267,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T10:21:36.336Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00069641",
      "title": "Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Mucopolysaccharidosis II"
      ],
      "interventions": [
        {
          "name": "iduronate-2-sulfatase enzyme replacement therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "5 Years to 25 Years · Male only"
      },
      "enrollment_count": 96,
      "start_date": "2003-09-18",
      "completion_date": "2005-03-16",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 4,
      "location_summary": "Oakland, California • St Louis, Missouri • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069641"
    },
    {
      "nct_id": "NCT00726739",
      "title": "Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "allogeneic large multivalent immunogen vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2008-06",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00726739"
    },
    {
      "nct_id": "NCT01153919",
      "title": "Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Infection",
        "Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "romiplostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "PEG-interferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-06-30",
      "completion_date": "2018-07-14",
      "has_results": false,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01153919"
    },
    {
      "nct_id": "NCT00259857",
      "title": "Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Alendronate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "5 Years to 15 Years"
      },
      "enrollment_count": 22,
      "start_date": "2003-10",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2011-01-19",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00259857"
    },
    {
      "nct_id": "NCT06295094",
      "title": "The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer",
        "Chemotherapy, Adjuvant",
        "Peritoneal Metastases",
        "Minimally Invasive Surgical Procedures"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Odense University Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 264,
      "start_date": "2024-09",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-06",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06295094"
    },
    {
      "nct_id": "NCT01030575",
      "title": "Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infant, Newborn",
        "Infant, Low Birth Weight",
        "Infant, Small for Gestational Age",
        "Infant, Premature",
        "Retinopathy of Prematurity",
        "Bronchopulmonary Dysplasia (BPD)"
      ],
      "interventions": [
        {
          "name": "Inositol lower volume",
          "type": "DRUG"
        },
        {
          "name": "Inositol mid-level volume",
          "type": "DRUG"
        },
        {
          "name": "Inositol high volume",
          "type": "DRUG"
        },
        {
          "name": "Placebo low volume",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Hours",
        "maximum_age": "72 Hours",
        "sex": "ALL",
        "summary": "12 Hours to 72 Hours"
      },
      "enrollment_count": 125,
      "start_date": "2010-01",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2022-06-14",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01030575"
    },
    {
      "nct_id": "NCT00024544",
      "title": "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "anti-IL-4 monoclonal antibody (pascolizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Facet Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2001-08",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-07",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Mission Viejo, California • Orange, California + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00024544"
    },
    {
      "nct_id": "NCT05099965",
      "title": "Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "HIV Infections",
        "Vaccine"
      ],
      "interventions": [
        {
          "name": "CMV-MVA Triplex",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 94,
      "start_date": "2021-11-02",
      "completion_date": "2025-10-08",
      "has_results": true,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099965"
    },
    {
      "nct_id": "NCT02056873",
      "title": "Tourette Syndrome Deep Brain Stimulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "Continuous DBS",
          "type": "DEVICE"
        },
        {
          "name": "Responsive Brain Stimulation (RBS Setting)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-03-20",
      "completion_date": "2023-08-24",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02056873"
    },
    {
      "nct_id": "NCT04682405",
      "title": "Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Uproleselan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 51,
      "start_date": "2021-05-05",
      "completion_date": "2022-11-11",
      "has_results": true,
      "last_update_posted_date": "2023-12-15",
      "last_synced_at": "2026-10-28T10:21:36.336Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04682405"
    }
  ]
}